| Catalog No. | DV185028 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 42.86 ng/mL |
|---|
| Range | 125 - 8,000 ng/mL |
|---|
| Accession | Q9BQB4 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
|---|
| Specifications | Romosozumab |
|---|
| Alternate Names | 785A070802, AMG 785, CDP-7851, romosozumab-aqqg, sclerostin Ab, CAS: 909395-70-6 |
|---|
| Background | Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. |
|---|
| Note | For Research Use Only. |
|---|
